CLE-100

esketamine · Clexio Biosciences Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for CLE-100, covering 2025-09-24 to 2026-06-23. Get the full timeline:

Most recent: Clinical Trial Results: A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder [Phase 2]

See pricing